Quince Therapeutics, Inc. — Director's Dealing 2021

Jun 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cortexyme, Inc. (CRTX)
CIK: 0001662774
Period of Report: 2021-06-16

Reporting Person: McLoughlin Margaret (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-16	Stock Option (right to buy)	$50.56	A	11029	Acquired	2031-06-15	Common Stock (11029)	Direct

Footnotes

F1: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 16, 2021.